FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Semax

ACTH 4-10 analog / Heptapeptide Semax

Cognitive & Neuro

Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a neuroprotective and nootropic agent. It is approved in Russia and Ukraine for the treatment of stroke, transient ischemic attacks, cognitive disorders, optic nerve atrophy, and peptic ulcers. Semax enhances BDNF expression, modulates serotonergic and dopaminergic neurotransmission, and provides neuroprotection without any hormonal (adrenocorticotropic) activity despite its ACTH-derived structure.

作用機序

Synthetic analog of ACTH 4-10 fragment with a Pro-Gly-Pro C-terminal extension. Increases BDNF and NGF expression in the hippocampus. Enhances attention, memory, and learning without hormonal effects of full-length ACTH. Neuroprotective against oxidative stress.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 200-600mcg intranasally 2-3 times daily. Russian approved protocols use 0.1% or 1% nasal drops. Higher concentrations (1%) used for acute neuroprotection. Typical cycles are 2-4 weeks.

研究ノート

Clinical Research Status

Semax has been approved in Russia since 2001 as a nasal spray (0.1% and 1% solutions) for acute ischemic stroke, cognitive impairment, and optic nerve diseases. Large-scale Russian clinical trials involving stroke patients demonstrated reduced neurological deficit scores and improved functional outcomes when administered within 6 hours of ischemic events. It has not entered FDA regulatory pathways and remains unapproved in Western markets. The 1% formulation (N-Acetyl Semax Amidate, or NASA) is used in more severe neurological conditions while the 0.1% is used for cognitive enhancement.

Key Published Findings

A 2005 study in Doklady Biological Sciences showed Semax increased BDNF mRNA expression in the rat hippocampus and basal forebrain by 1.4-3x baseline within 24 hours. Clinical stroke trials published in Zhurnal Nevrologii i Psikhiatrii demonstrated 2.4x faster neurological recovery versus controls when administered acutely. Semax was shown to differentially regulate 24 genes in glial cells related to neuroinflammation and neuroprotection in a 2013 transcriptomics study. Research confirms no adrenocorticotropic effects despite the ACTH backbone, as the melanocortin-receptor binding motif was deliberately excluded from the fragment.

Safety Profile

Extensive clinical use in Russia over 20+ years has revealed no significant adverse effects, hormonal disruption, or organ toxicity. Semax produces no sedation, tolerance, withdrawal, or dependence, and no drug-related deaths have been reported. The peptide is rapidly degraded by aminopeptidases with a plasma half-life of approximately 2 minutes, though CNS effects persist for 20-24 hours due to intracellular signaling cascades. Nasal administration avoids first-pass metabolism and achieves CNS penetration without systemic accumulation.

Drug Interactions & Contraindications

No formally documented drug interactions exist in published literature, though the serotonergic modulation suggests theoretical caution with SSRIs or MAOIs at high doses. Contraindicated in patients with acute psychosis or severe manic episodes due to its stimulating cognitive effects. May theoretically potentiate the effects of stimulant medications (amphetamines, methylphenidate) through dopaminergic enhancement. Not recommended in pregnancy due to insufficient safety data despite the absence of hormonal activity.

Comparison to Related Compounds

Semax is more stimulating and neuroprotective compared to Selank, which is primarily anxiolytic; Russian clinicians frequently prescribe them together for complementary effects. Unlike racetam nootropics, Semax has a well-defined mechanism (BDNF upregulation, TrkB signaling) and documented neuroprotective efficacy in stroke. Compared to cerebrolysin (another Russian-approved neuroprotective), Semax offers non-invasive nasal administration versus required IV infusion. The N-Acetyl Semax Amidate (NASA) analog offers approximately 60x greater stability and potency versus unmodified Semax.

Community Observations

Users report enhanced verbal fluency, motivation, and mental clarity typically within 10-30 minutes of intranasal administration, lasting 4-8 hours. The 0.1% solution (50 mcg/drop) is most commonly used at 2-3 drops per nostril, 2-3 times daily for cognitive enhancement. Some users report a mild stimulant-like quality that can interfere with sleep if dosed too late in the day. Combining Semax with Selank is considered the gold-standard peptide nootropic stack in the biohacking community, providing focused cognition without anxiety.

半減期

~2-3 minutes (intranasal effects last 4-6 hours)

再構成

Bacteriostatic water (BAC) for SubQ; saline for nasal

保存

乾燥粉末

Refrigerate 2-8C up to 12 months.

再溶解

Refrigerate 2-8C. Use within 14 days.

米国法的状況

Research chemical (approved in Russia)

また知られる名前

ACTH 4-10 analogHeptapeptide Semax

よくある質問

Semaxとは何ですか?

Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a neuroprotective and nootropic agent. It is approved in Russia and Ukraine for the treatment of stroke, transient ischemic attacks, cognitive disorders, optic nerve atrophy, and peptic ulcers. Semax enhances BDNF expression, modulates serotonergic and dopaminergic neurotransmission, and provides neuroprotection without any hormonal (adrenocorticotropic) activity despite its ACTH-derived structure.

Semaxはどのように作用しますか?

Synthetic analog of ACTH 4-10 fragment with a Pro-Gly-Pro C-terminal extension. Increases BDNF and NGF expression in the hippocampus. Enhances attention, memory, and learning without hormonal effects of full-length ACTH. Neuroprotective against oxidative stress.

Semaxの米国での規制状況は?

Research chemical (approved in Russia)

Semaxの半減期は?

~2-3 minutes (intranasal effects last 4-6 hours)

Semaxの別名は?

ACTH 4-10 analog, Heptapeptide Semax

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む